SlideShare a Scribd company logo
CLAAD & Safe BTW
 National Dialogue on
Drug-Impaired Driving

       April 10-12, 2012
Walt Disney World Swan Resort
Policy Goals
•  Identifying Drug-Impaired Drivers

•  Distinguishing mere medication use from
   actual cognitive impairment.
Statistics
Drug-impaired driving can have fatal
  consequences:

•    In 2009, 13,801 drivers who died in car crashes
     tested positive for drugs.
•    63% of all tested drivers who died in car crashes
     tested positive for drug use.
•    A California study found 1 in every 10 people
     killed in car crashes was drug-impaired.
Dangers of
         Drug-Impaired Driving
•    Drivers ignore labels warning against operating heavy
     machinery.
•    Driving after taking medication affects the brain.
•    Medications can impair judgment, motor skills,
     perception, and memory.
•    Drivers, passengers, and others on the road are at risk.
Prevention: DUID Laws
All states have DUID statutes. Most states use one
of three types of drugged-driving laws:
1. Statutes requiring driver to be incapable of driving safely (14
states);
2. Statutes requiring driver to be under the influence or affected
by an intoxicating drug (8 states); and
3. Per se or zero tolerance statutes. (17 states)

5 states prohibit any addicted person or habitual
user to drive at all.
DUID Law Defenses
•  20 states: valid prescription is not legal defense.
•  5 states: valid prescription as long as used as
   directed is legal defense.
•  Maryland: valid prescription is legal defense if
   defendant was unaware of drug s effect.
Statutes with Subjective
                Standards
DUID Statutes contain subjective standards:
•     Incapacity : connection between drug ingestion and
     the incapacity of the driver
•     Under the influence : impairment is directly related to
     drug ingestion
•     Per se : drug is in the driver s system.
•    Determination of drug use based on blood, urine, saliva,
     or other bodily fluid tests.
Prevention: Common Law
States have also developed common law doctrines to
   prevent drug-impaired driving.
  –    Massachusetts: liability for physicians for failure to warn
       against driving if such failure results in third-party death.
  –    Alabama: imposed liability on a Methadone Clinic for
       administering methadone and releasing a patient who
       killed a third party while driving.
Prevention: Common Law
•    Florida: Judge will suspend drivers licenses for
     using oxycodone.
•    Patients are responsible for obtaining a doctor s
     letter.
•    Prescribers are at a greater risk for liability.
Drug-Impaired Laws Lag Behind
      Alcohol-Impaired Laws
•    Drugged-driving laws lag behind alcohol-impaired
     driving law.

•    Why?
     –    Technological limitations in testing.
     –    No agreed-upon impairment limit.
     –    Drugs linger in the body.
Current Methods of Identifying
      Impaired Drivers
Drug Recognition and Classification Programs (DEC)
  •    49 states and D.C. have Drug Evaluation and
       Classification Programs.
  •    DREs receive training to identify drug-impaired drivers and
       determine the drug category.
  •    Programs rely on observations.
  •    Categories are based on signs and symptoms.
Current Methods of Identifying
      Impaired Drivers
Blood and Urine Testing
  •    34 states test blood, urine, saliva, or other bodily
       substances.
  •    8 states allow blood only.
  •    6 states permit saliva.
  •    8 states permit other bodily substances.
Problems with Drug Evaluation
   and Classification Programs
•    Drug Evaluation and Classification Programs lack
     scientific precision.
•    Blood and urine tests cannot determine whether
     drivers were actually impaired while driving.
What can we do?
•    Encourage states to adopt clearer standards for Per Se
     laws;
•    Collect additional data on drug-impaired driving;
•    Prevent drug-impaired driving by educating communities
     and professionals;
•    Provide increased training to law enforcement on
     identifying drug-impaired drivers; and
•    Develop standard methodologies for drug-testing labs to
     use in detecting the presence of drugs.
•    Encourage prescribers to help by recognizing patients
     with substance-abuse problems and developing
     strategies with their patients to overcome such problems.
Suggestions?
What preventative strategies do you think would
  help with the following issue?
  •    Identify impaired drivers.
  •    Distinguish mere medication use from actual
       cognitive impairment.
  •    Incentivize individuals to refrain from driving
       while drug-impaired.
For More Information on Drug-
       Impaired Driving
 Contact:
   Paul Scott O Neill, CLAAD Policy Advisor
   (703) 527-4550
   pso@claad.org
   www.claad.org

   Stacey Sklaver, Safe BTW Policy Advisor
   (703) 527-8800
   sls@safebtw.org
   www.safebtw.org

More Related Content

What's hot

Dayton - opiate prescription abuse in utah
Dayton - opiate prescription abuse in utahDayton - opiate prescription abuse in utah
Dayton - opiate prescription abuse in utah
John Dayton, MD, FACEP, FAAEM
 
CR_drug_abuse_2016
CR_drug_abuse_2016CR_drug_abuse_2016
CR_drug_abuse_2016
Natalie Bishop
 
Ph 4 rannizzisi
Ph 4 rannizzisiPh 4 rannizzisi
Ph 4 rannizzisi
OPUNITE
 
Veterinary Drug Diversion Solutions
Veterinary Drug Diversion SolutionsVeterinary Drug Diversion Solutions
Veterinary Drug Diversion Solutions
TheTitanGroupLLC
 
Driving Home the Point: Medicines, Impaired Driving, and You
Driving Home the Point: Medicines, Impaired Driving, and YouDriving Home the Point: Medicines, Impaired Driving, and You
Driving Home the Point: Medicines, Impaired Driving, and You
RADDOrg
 
Drug testing in the workplace
Drug testing in the workplaceDrug testing in the workplace
Drug testing in the workplace
jsoto74
 
Addressing drug use and changing legal and social
Addressing drug use and changing legal and socialAddressing drug use and changing legal and social
Addressing drug use and changing legal and social
Greg Chartier, PhD
 
Urine Toxicology Testing
Urine Toxicology TestingUrine Toxicology Testing
Urine Toxicology Testing
yury
 
Revised rx16 treat_tues_415_1_volkow_2dupont
Revised rx16 treat_tues_415_1_volkow_2dupontRevised rx16 treat_tues_415_1_volkow_2dupont
Revised rx16 treat_tues_415_1_volkow_2dupont
OPUNITE
 
United Arab Emirates Pharmacists’ Practices and Views on Adverse Drug Reactio...
United Arab Emirates Pharmacists’ Practices and Views on Adverse Drug Reactio...United Arab Emirates Pharmacists’ Practices and Views on Adverse Drug Reactio...
United Arab Emirates Pharmacists’ Practices and Views on Adverse Drug Reactio...
iosrjce
 
Pharmacist Prescription Drug Extension_Citations_edited_2015_05_07
Pharmacist Prescription Drug Extension_Citations_edited_2015_05_07Pharmacist Prescription Drug Extension_Citations_edited_2015_05_07
Pharmacist Prescription Drug Extension_Citations_edited_2015_05_07
Jessica Bigger
 
Understanding Georgian Pharmaceutical Law
Understanding Georgian Pharmaceutical LawUnderstanding Georgian Pharmaceutical Law
Understanding Georgian Pharmaceutical Law
Melinda_White
 
Ph 1 harris hanna_slack
Ph 1 harris hanna_slackPh 1 harris hanna_slack
Ph 1 harris hanna_slack
OPUNITE
 
Prescription Drug Abuse is on the Rise in Florida
Prescription Drug Abuse is on the Rise in FloridaPrescription Drug Abuse is on the Rise in Florida
Prescription Drug Abuse is on the Rise in Florida
Craig Benoit
 
ERs Face the Problem of Multiple Drugs in Overdose Patients
ERs Face the Problem of Multiple Drugs in Overdose PatientsERs Face the Problem of Multiple Drugs in Overdose Patients
ERs Face the Problem of Multiple Drugs in Overdose Patients
Medical Transcription Service Company
 
Web only rx16 len tues_1115_group
Web only rx16 len tues_1115_groupWeb only rx16 len tues_1115_group
Web only rx16 len tues_1115_group
OPUNITE
 
aidslinedec13
aidslinedec13aidslinedec13
aidslinedec13
Sarah Quinless
 
Safety measures while using medicine
Safety measures while using medicineSafety measures while using medicine
Safety measures while using medicine
Rahul Magnani
 
Emerging public health issue: Prescription Overdose
Emerging public health issue: Prescription OverdoseEmerging public health issue: Prescription Overdose
Emerging public health issue: Prescription Overdose
Tosin Ola-Weissmann
 
“The Value of Drug Monitoring in Chronic Opioid Therapy Patients”
“The Value of Drug Monitoring in Chronic Opioid Therapy Patients”“The Value of Drug Monitoring in Chronic Opioid Therapy Patients”
“The Value of Drug Monitoring in Chronic Opioid Therapy Patients”
Fred Jorgensen
 

What's hot (20)

Dayton - opiate prescription abuse in utah
Dayton - opiate prescription abuse in utahDayton - opiate prescription abuse in utah
Dayton - opiate prescription abuse in utah
 
CR_drug_abuse_2016
CR_drug_abuse_2016CR_drug_abuse_2016
CR_drug_abuse_2016
 
Ph 4 rannizzisi
Ph 4 rannizzisiPh 4 rannizzisi
Ph 4 rannizzisi
 
Veterinary Drug Diversion Solutions
Veterinary Drug Diversion SolutionsVeterinary Drug Diversion Solutions
Veterinary Drug Diversion Solutions
 
Driving Home the Point: Medicines, Impaired Driving, and You
Driving Home the Point: Medicines, Impaired Driving, and YouDriving Home the Point: Medicines, Impaired Driving, and You
Driving Home the Point: Medicines, Impaired Driving, and You
 
Drug testing in the workplace
Drug testing in the workplaceDrug testing in the workplace
Drug testing in the workplace
 
Addressing drug use and changing legal and social
Addressing drug use and changing legal and socialAddressing drug use and changing legal and social
Addressing drug use and changing legal and social
 
Urine Toxicology Testing
Urine Toxicology TestingUrine Toxicology Testing
Urine Toxicology Testing
 
Revised rx16 treat_tues_415_1_volkow_2dupont
Revised rx16 treat_tues_415_1_volkow_2dupontRevised rx16 treat_tues_415_1_volkow_2dupont
Revised rx16 treat_tues_415_1_volkow_2dupont
 
United Arab Emirates Pharmacists’ Practices and Views on Adverse Drug Reactio...
United Arab Emirates Pharmacists’ Practices and Views on Adverse Drug Reactio...United Arab Emirates Pharmacists’ Practices and Views on Adverse Drug Reactio...
United Arab Emirates Pharmacists’ Practices and Views on Adverse Drug Reactio...
 
Pharmacist Prescription Drug Extension_Citations_edited_2015_05_07
Pharmacist Prescription Drug Extension_Citations_edited_2015_05_07Pharmacist Prescription Drug Extension_Citations_edited_2015_05_07
Pharmacist Prescription Drug Extension_Citations_edited_2015_05_07
 
Understanding Georgian Pharmaceutical Law
Understanding Georgian Pharmaceutical LawUnderstanding Georgian Pharmaceutical Law
Understanding Georgian Pharmaceutical Law
 
Ph 1 harris hanna_slack
Ph 1 harris hanna_slackPh 1 harris hanna_slack
Ph 1 harris hanna_slack
 
Prescription Drug Abuse is on the Rise in Florida
Prescription Drug Abuse is on the Rise in FloridaPrescription Drug Abuse is on the Rise in Florida
Prescription Drug Abuse is on the Rise in Florida
 
ERs Face the Problem of Multiple Drugs in Overdose Patients
ERs Face the Problem of Multiple Drugs in Overdose PatientsERs Face the Problem of Multiple Drugs in Overdose Patients
ERs Face the Problem of Multiple Drugs in Overdose Patients
 
Web only rx16 len tues_1115_group
Web only rx16 len tues_1115_groupWeb only rx16 len tues_1115_group
Web only rx16 len tues_1115_group
 
aidslinedec13
aidslinedec13aidslinedec13
aidslinedec13
 
Safety measures while using medicine
Safety measures while using medicineSafety measures while using medicine
Safety measures while using medicine
 
Emerging public health issue: Prescription Overdose
Emerging public health issue: Prescription OverdoseEmerging public health issue: Prescription Overdose
Emerging public health issue: Prescription Overdose
 
“The Value of Drug Monitoring in Chronic Opioid Therapy Patients”
“The Value of Drug Monitoring in Chronic Opioid Therapy Patients”“The Value of Drug Monitoring in Chronic Opioid Therapy Patients”
“The Value of Drug Monitoring in Chronic Opioid Therapy Patients”
 

Similar to CLAAD/ Safe BTW

Chapter 8
Chapter 8Chapter 8
Chapter 8
krobinson-ucn
 
Drugged Driving Datia Conference Presentation 2012
Drugged Driving   Datia Conference Presentation 2012Drugged Driving   Datia Conference Presentation 2012
Drugged Driving Datia Conference Presentation 2012
Lifeloc Technologies
 
Favorite slides for safety meeting and drug awareness
Favorite slides for safety meeting and drug awarenessFavorite slides for safety meeting and drug awareness
Favorite slides for safety meeting and drug awareness
Michael Kennedy
 
Role of drug regulatory agencies in Clinical Research
Role of drug regulatory agencies in Clinical ResearchRole of drug regulatory agencies in Clinical Research
Role of drug regulatory agencies in Clinical Research
ClinosolIndia
 
NADAP July 2013 E-Gram
NADAP July 2013 E-GramNADAP July 2013 E-Gram
NADAP July 2013 E-Gram
Sara Sisung
 
Role of Drug Regulatory agencies in Clinical Research.
Role of Drug Regulatory agencies in Clinical Research.Role of Drug Regulatory agencies in Clinical Research.
Role of Drug Regulatory agencies in Clinical Research.
ClinosolIndia
 
Drug Addiction And Youth’s of Bangladesh
Drug Addiction And Youth’s of BangladeshDrug Addiction And Youth’s of Bangladesh
Drug Addiction And Youth’s of Bangladesh
Ayesha Sultana
 
Legalization of Marijuana Webinar- Impact for Drug Testing Employers
Legalization of Marijuana Webinar- Impact for Drug Testing Employers Legalization of Marijuana Webinar- Impact for Drug Testing Employers
Legalization of Marijuana Webinar- Impact for Drug Testing Employers
Eliassen Group
 
New Zealand Drug Courts: Driven by ideology or evidence?
New Zealand Drug Courts: Driven by ideology or evidence?New Zealand Drug Courts: Driven by ideology or evidence?
New Zealand Drug Courts: Driven by ideology or evidence?
Julian Buchanan
 
Substance Abuse in Canada
Substance Abuse in CanadaSubstance Abuse in Canada
Substance Abuse in Canada
michaeljcasey
 
Drug driving legislation - how are you affected?
Drug driving legislation - how are you affected?Drug driving legislation - how are you affected?
Drug driving legislation - how are you affected?
Richard Evers
 
Cannabis Science & Policy Summit - Day 1 - Kagan
Cannabis Science & Policy Summit - Day 1 - KaganCannabis Science & Policy Summit - Day 1 - Kagan
Cannabis Science & Policy Summit - Day 1 - Kagan
CannabisSummit
 
State profile -_new_york_0
State profile -_new_york_0State profile -_new_york_0
State profile -_new_york_0
satoriwatersfl
 
Substance abuse assessment
Substance abuse assessmentSubstance abuse assessment
Substance abuse assessment
Vivian Olgah Kudda
 
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonickRx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
OPUNITE
 
State profile -_florida
State profile -_floridaState profile -_florida
State profile -_florida
satoriwatersfl
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf
ASSAM DOWN TOWN UNIVERSITY
 
Drunkdriving
DrunkdrivingDrunkdriving
Drunkdriving
Sarah Meers
 
Alcohol, tobacco and other drugs
Alcohol, tobacco and other drugsAlcohol, tobacco and other drugs
Alcohol, tobacco and other drugs
emy1353
 

Similar to CLAAD/ Safe BTW (20)

Chapter 8
Chapter 8Chapter 8
Chapter 8
 
Drugged Driving Datia Conference Presentation 2012
Drugged Driving   Datia Conference Presentation 2012Drugged Driving   Datia Conference Presentation 2012
Drugged Driving Datia Conference Presentation 2012
 
Favorite slides for safety meeting and drug awareness
Favorite slides for safety meeting and drug awarenessFavorite slides for safety meeting and drug awareness
Favorite slides for safety meeting and drug awareness
 
drug_toxicology_for_prosecutors_04
drug_toxicology_for_prosecutors_04drug_toxicology_for_prosecutors_04
drug_toxicology_for_prosecutors_04
 
Role of drug regulatory agencies in Clinical Research
Role of drug regulatory agencies in Clinical ResearchRole of drug regulatory agencies in Clinical Research
Role of drug regulatory agencies in Clinical Research
 
NADAP July 2013 E-Gram
NADAP July 2013 E-GramNADAP July 2013 E-Gram
NADAP July 2013 E-Gram
 
Role of Drug Regulatory agencies in Clinical Research.
Role of Drug Regulatory agencies in Clinical Research.Role of Drug Regulatory agencies in Clinical Research.
Role of Drug Regulatory agencies in Clinical Research.
 
Drug Addiction And Youth’s of Bangladesh
Drug Addiction And Youth’s of BangladeshDrug Addiction And Youth’s of Bangladesh
Drug Addiction And Youth’s of Bangladesh
 
Legalization of Marijuana Webinar- Impact for Drug Testing Employers
Legalization of Marijuana Webinar- Impact for Drug Testing Employers Legalization of Marijuana Webinar- Impact for Drug Testing Employers
Legalization of Marijuana Webinar- Impact for Drug Testing Employers
 
New Zealand Drug Courts: Driven by ideology or evidence?
New Zealand Drug Courts: Driven by ideology or evidence?New Zealand Drug Courts: Driven by ideology or evidence?
New Zealand Drug Courts: Driven by ideology or evidence?
 
Substance Abuse in Canada
Substance Abuse in CanadaSubstance Abuse in Canada
Substance Abuse in Canada
 
Drug driving legislation - how are you affected?
Drug driving legislation - how are you affected?Drug driving legislation - how are you affected?
Drug driving legislation - how are you affected?
 
Cannabis Science & Policy Summit - Day 1 - Kagan
Cannabis Science & Policy Summit - Day 1 - KaganCannabis Science & Policy Summit - Day 1 - Kagan
Cannabis Science & Policy Summit - Day 1 - Kagan
 
State profile -_new_york_0
State profile -_new_york_0State profile -_new_york_0
State profile -_new_york_0
 
Substance abuse assessment
Substance abuse assessmentSubstance abuse assessment
Substance abuse assessment
 
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonickRx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
 
State profile -_florida
State profile -_floridaState profile -_florida
State profile -_florida
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf
 
Drunkdriving
DrunkdrivingDrunkdriving
Drunkdriving
 
Alcohol, tobacco and other drugs
Alcohol, tobacco and other drugsAlcohol, tobacco and other drugs
Alcohol, tobacco and other drugs
 

More from OPUNITE

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
OPUNITE
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
OPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
OPUNITE
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
OPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
OPUNITE
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
OPUNITE
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
OPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
OPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
OPUNITE
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
OPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
OPUNITE
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
OPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
OPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
OPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
OPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
OPUNITE
 

More from OPUNITE (20)

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 

Recently uploaded

The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
MedicoseAcademics
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
All info about Diabetes and how to control it.
 All info about Diabetes and how to control it. All info about Diabetes and how to control it.
All info about Diabetes and how to control it.
Gokuldas Hospital
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loopLOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
debosmitaasanyal1
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
DIVYANSHU740006
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 

Recently uploaded (20)

The Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic PrinciplesThe Electrocardiogram - Physiologic Principles
The Electrocardiogram - Physiologic Principles
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
All info about Diabetes and how to control it.
 All info about Diabetes and how to control it. All info about Diabetes and how to control it.
All info about Diabetes and how to control it.
 
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loopLOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
LOOPS in orthodontics t loop bull loop vertical loop mushroom loop stop loop
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 

CLAAD/ Safe BTW

  • 1. CLAAD & Safe BTW National Dialogue on Drug-Impaired Driving April 10-12, 2012 Walt Disney World Swan Resort
  • 2. Policy Goals •  Identifying Drug-Impaired Drivers •  Distinguishing mere medication use from actual cognitive impairment.
  • 3. Statistics Drug-impaired driving can have fatal consequences: •  In 2009, 13,801 drivers who died in car crashes tested positive for drugs. •  63% of all tested drivers who died in car crashes tested positive for drug use. •  A California study found 1 in every 10 people killed in car crashes was drug-impaired.
  • 4. Dangers of Drug-Impaired Driving •  Drivers ignore labels warning against operating heavy machinery. •  Driving after taking medication affects the brain. •  Medications can impair judgment, motor skills, perception, and memory. •  Drivers, passengers, and others on the road are at risk.
  • 5. Prevention: DUID Laws All states have DUID statutes. Most states use one of three types of drugged-driving laws: 1. Statutes requiring driver to be incapable of driving safely (14 states); 2. Statutes requiring driver to be under the influence or affected by an intoxicating drug (8 states); and 3. Per se or zero tolerance statutes. (17 states) 5 states prohibit any addicted person or habitual user to drive at all.
  • 6. DUID Law Defenses •  20 states: valid prescription is not legal defense. •  5 states: valid prescription as long as used as directed is legal defense. •  Maryland: valid prescription is legal defense if defendant was unaware of drug s effect.
  • 7. Statutes with Subjective Standards DUID Statutes contain subjective standards: •  Incapacity : connection between drug ingestion and the incapacity of the driver •  Under the influence : impairment is directly related to drug ingestion •  Per se : drug is in the driver s system. •  Determination of drug use based on blood, urine, saliva, or other bodily fluid tests.
  • 8. Prevention: Common Law States have also developed common law doctrines to prevent drug-impaired driving. –  Massachusetts: liability for physicians for failure to warn against driving if such failure results in third-party death. –  Alabama: imposed liability on a Methadone Clinic for administering methadone and releasing a patient who killed a third party while driving.
  • 9. Prevention: Common Law •  Florida: Judge will suspend drivers licenses for using oxycodone. •  Patients are responsible for obtaining a doctor s letter. •  Prescribers are at a greater risk for liability.
  • 10. Drug-Impaired Laws Lag Behind Alcohol-Impaired Laws •  Drugged-driving laws lag behind alcohol-impaired driving law. •  Why? –  Technological limitations in testing. –  No agreed-upon impairment limit. –  Drugs linger in the body.
  • 11. Current Methods of Identifying Impaired Drivers Drug Recognition and Classification Programs (DEC) •  49 states and D.C. have Drug Evaluation and Classification Programs. •  DREs receive training to identify drug-impaired drivers and determine the drug category. •  Programs rely on observations. •  Categories are based on signs and symptoms.
  • 12. Current Methods of Identifying Impaired Drivers Blood and Urine Testing •  34 states test blood, urine, saliva, or other bodily substances. •  8 states allow blood only. •  6 states permit saliva. •  8 states permit other bodily substances.
  • 13. Problems with Drug Evaluation and Classification Programs •  Drug Evaluation and Classification Programs lack scientific precision. •  Blood and urine tests cannot determine whether drivers were actually impaired while driving.
  • 14. What can we do? •  Encourage states to adopt clearer standards for Per Se laws; •  Collect additional data on drug-impaired driving; •  Prevent drug-impaired driving by educating communities and professionals; •  Provide increased training to law enforcement on identifying drug-impaired drivers; and •  Develop standard methodologies for drug-testing labs to use in detecting the presence of drugs. •  Encourage prescribers to help by recognizing patients with substance-abuse problems and developing strategies with their patients to overcome such problems.
  • 15. Suggestions? What preventative strategies do you think would help with the following issue? •  Identify impaired drivers. •  Distinguish mere medication use from actual cognitive impairment. •  Incentivize individuals to refrain from driving while drug-impaired.
  • 16. For More Information on Drug- Impaired Driving Contact: Paul Scott O Neill, CLAAD Policy Advisor (703) 527-4550 pso@claad.org www.claad.org Stacey Sklaver, Safe BTW Policy Advisor (703) 527-8800 sls@safebtw.org www.safebtw.org